BARD1 and neoplasm: Genetic testing revealed Class II variants with potential clinical significance: ATR: c.6078 + 1G>T (intron 35, VAF: 18.80%); BARD1: p.M420Ifs8 (exon 4, VAF: 16.96%); SMARCA4: p.G256* (exon 5, VAF: 51.82%); and TP53: p.M66Gfs75 (exon 14, VAF: 24.33%); and Level III variants with potential biological significance: NSD1 p.R1700* (exon 14, VAF: 24.33%); microsatellite instability (MSI) was not detected as MSI-H; and tumor mutational burden (TMB) was 27.8 mutations/Mb, indicating high TMB (Table 1).